GH-21
- Generic Name
- GH-21
Yifang Biopharma's TYK2 Inhibitor D-2570 Shows Promising Phase II Results in Psoriasis Treatment
• Yifang Biopharma's TYK2 inhibitor, D-2570, demonstrated significant efficacy in a Phase II trial for moderate to severe plaque psoriasis, with high PASI 75 response rates across multiple dose groups.
• The Phase II trial of D-2570 met its primary endpoint, showing statistically significant improvements in psoriasis symptoms compared to placebo, with a favorable safety profile.
• Gesolexab (D-1553), a KRAS G12C inhibitor developed by Yifang Biopharma, has completed first subject enrollment in Phase III clinical study for non-small cell lung cancer.
• D-0502, an oral selective estrogen receptor degrader (SERD), is currently in Phase III clinical trials for second-line treatment of ER-positive, HER2-negative breast cancer, showing promising clinical benefit.
Significant Advances and Collaborations Among Viva's Portfolio Companies
Viva's portfolio companies have made notable progress in biopharmaceutical innovation, including funding achievements, clinical trial advancements, and strategic collaborations aimed at developing novel therapies for various diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath